Physician profile
Neil Jagdish Mehta
NPI 1235293325
$60,420.04
in general payments reported to CMS, 2019-2025
10 companies · $25K in 2025
The $25K reported for 2025 was more than what 78% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $1,650 · 2022: $6,937 · 2023: $17K · 2024: $8,390 · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $2,589 · Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,695.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,038.50 |
| Travel and Lodging | $2,589.27 |
| Food and Beverage | $1,213.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21,960.00 | 2022-2023 | |
| Fujifilm Healthcare Americas Corporation | $17,795.04 | 2022-2025 | Utaswako Afp-L3 |
| Boston Scientific Corporation | $7,689.95 | 2025 | General - Interventional Oncology |
| Sirtex Medical INC | $3,650.00 | 2025 | Sir-Spheres Microspheres |
| Astrazeneca Pharmaceuticals Lp | $3,623.51 | 2024-2025 | Imfinzi |
| Genentech, INC. | $2,713.60 | 2024 | Tecentriq |
| Exelixis INC. | $1,650.00 | 2020 | |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $1,202.23 | 2019 | |
| Biocompatibles, INC. | $93.75 | 2019 | |
| Genentech USA, INC. | $41.96 | 2023 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.